All In Biotech

Free tool

FAERS Monitor: Avlayah

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761485 or its brand name (Avlayah, Tividenofusp Alfa-Eknm). Reports on generic versions are filed under their own applications.

Reports

8

Serious

7

88% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • infusion related reaction5
  • cough3
  • oxygen saturation decreased3
  • urticaria3
  • dyspnoea2
  • chills1
  • discomfort1
  • erythema1
  • eye swelling1
  • flushing1
  • hypopnoea1
  • hypoxia1
  • periorbital oedema1
  • pruritus1
  • pyrexia1

Reports by year received

View as table
YearReports
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,151 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypopnoea1757.8121.1188
periorbital oedema1506.581.0126
infusion related reactionSignal5198.3115.9797
oxygen saturation decreasedSignal3140.457.4288
hypoxia174.711.918
eye swelling170.711.317
urticariaSignal347.119.294
discomfort143.16.910
coughSignal328.111.554
flushing125.94.16
chills122.43.65
erythema112.82.02
dyspnoea29.32.88
pyrexia17.61.21
pruritus16.81.11

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.